Forte Biosciences, Inc.
NASDAQ:FBRX · NASDAQ Capital Market
+$0.30 today
Vol 0.17M · Avg 0.30M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:FBRX · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$75.9M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-4.58, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $64.0K +64.1% | $39.0K +333.3% | $9.0K | $0 -100.0% | $36.0K | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$64.0K -64.1% | -$39.0K -333.3% | -$9.0K | $0 +100.0% | -$36.0K | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $58.2M +174.8% | $21.2M -3.1% | $21.9M +290.8% | $5.6M -59.6% | $13.9M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $12.4M -19.3% | $15.4M +44.8% | $10.6M +27.9% | $8.3M +8.8% | $7.6M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $70.7M +93.2% | $36.6M +12.6% | $32.5M +133.7% | $13.9M -35.3% | $21.5M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $64.0K +64.1% | $39.0K +333.3% | $9.0K -75.0% | $36.0K +0.0% | $36.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$68.3M -92.7% | -$35.4M -12.6% | -$31.5M -127.3% | -$13.8M +36.1% | -$21.7M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$70.7M -93.0% | -$36.6M -12.7% | -$32.5M -133.8% | -$13.9M +35.3% | -$21.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $2.7M +106.6% | $1.3M +16.9% | $1.1M | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $2.3M +106.3% | $1.1M +11.3% | $1.0M +5841.2% | $17.0K +107.7% | -$222.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$68.3M -92.6% | -$35.5M -12.7% | -$31.5M -126.8% | -$13.9M +36.1% | -$21.7M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $1.0M | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$69.4M -95.5% | -$35.5M -12.7% | -$31.5M -127.1% | -$13.9M +36.1% | -$21.7M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$5 +61.3% | -$12 +51.2% | -$25 -24.8% | -$20 +48.6% | -$39 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$5 +61.3% | -$12 +51.2% | -$25 -24.8% | -$20 +48.6% | -$39 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $147.2M +4947.4% | $2.9M +130.9% | $1.3M +81.6% | $695.3K +24.5% | $558.7K | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $147.2M +4947.4% | $2.9M +130.9% | $1.3M +81.6% | $695.3K +24.5% | $558.7K | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Fate Therapeutics, Inc.
NASDAQ:FATE
$228.46M
Nkarta, Inc.
NASDAQ:NKTX
$195.68M
Alector, Inc.
NASDAQ:ALEC
$181.53M
Molecular Partners AG
NASDAQ:MOLN
$147.42M
PepGen Inc.
NASDAQ:PEPG
$123.81M
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
$101.88M
Cardiff Oncology, Inc.
NASDAQ:CRDF
$82.73M
Elicio Therapeutics, Inc.
NASDAQ:ELTX
$72.15M
Actuate Therapeutics Inc
NASDAQ:ACTU
$51.20M
Applied Therapeutics, Inc.
APLT
$14.86M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does FBRX generate?
Forte Biosciences, Inc. (FBRX) reported $0.00 of revenue in fiscal 2025.
Is FBRX profitable?
Forte Biosciences, Inc. (FBRX) reported -$69,375,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.